Xenpozyme is the first approved medication to treat symptoms that are not related to the central nervous system in patients with ASMD, a rare genetic disease that causes premature death.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
ZURICH (Reuters) – Food group Nestle has taken a further step into the medicine business by signing a research collaboration agreement with a Swiss biotech company to develop an Alzheimer’s disease diagnostic test. Nestle’s second medical deal in a week underscores the commitment by the world’s largest packaged food company to the faster-growing, more profitable […]
Israel-based drugmaker Teva Pharmaceutical (TEVA) is snapping up Allergan Plc’s generic drug business for $40.5 billion, the company announced this morning. Under terms of the agreement, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion, representing an estimated under 10 percent ownership stake in Teva, the company said. […]
Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer’s disease Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer’s; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose Exelon Patch first and only transdermal therapy approved to treat […]